EQS — News: Eckert & Ziegler and TerThera Sign Supply Agreement to Bring Next — Generation GMP Terbium — 161 Radiopharmaceutical Therapies to Brazilian Patient

EQS-News: Eckert & Ziegler SE / Key word(s): Contract Eckert & Ziegler and TerThera Sign Supply Agreement to Bring Next-Generation GMP Terbium-161 Radiopharmaceutical Therapies to Brazilian Patient 13.10.2026 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. ══════════════════════════════════════════════════════════════════════════ Berlin/Breda, 13 October 2026. Eckert & Ziegler Brazil, a regional subsidiary of the global nuclear medicine group Eckert & Ziegler SE (ISIN DE0005659700, TecDAX), and TerThera announced today the signing of a strategic supply agreement for the precursor Terbium-161. Under the terms of the agreement, TerThera will supply its GMP-compliant non-carrier-added (n.c.a.) Terbium-161 (Tb-161) to Eckert & Ziegler Brazil. This partnership establishes a critical and reliable supply chain for the innovative isotope in South America, directly providing Brazilian patients access to the next generation of radioligand therapies. Moreover, the availability of GMP-grade Tb-161 will allow local pharmaceutical developers and clinical institutions to investigate the combination of Tb-161 with novel peptides, antibodies, and FAP-inhibito